MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$112,569K
EPS
-$1.09
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
Research and development
101,061
70,873
General and administrative
20,312
13,787
Total operating expenses
121,373
84,660
Loss from operations
-121,373
-84,660
Interest income
9,994
5,716
Other income, net
-
79
Other income (expense), net
72
5,795
Total other income
10,066
-
Net loss
-111,307
-78,865
Unrealized loss
-1,262
-761
Comprehensive loss
-112,569
-79,626
Basic EPS
-1.09
-3,650
Diluted EPS
-1.09
-3,650
Basic Average Shares
102,226,608
21,607
Diluted Average Shares
102,226,608
21,607
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$112,569K
Interest income
$9,994K
Other income
(expense), net
$72K
Net loss
-$111,307K
Unrealized loss
-$1,262K
Total other income
$10,066K
Loss from operations
-$121,373K
Total operating
expenses
$121,373K
Research and development
$101,061K
General and
administrative
$20,312K
Buy us a coffee
Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics, Inc. (KLRA)